Immunogenicity of influenza virus vaccine, meningococcal vaccines +/- secukinumab in adult subjects

Trial Profile

Immunogenicity of influenza virus vaccine, meningococcal vaccines +/- secukinumab in adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2012

At a glance

  • Drugs Secukinumab (Primary) ; Influenza virus vaccine; Meningococcal vaccine group C conjugate; Meningococcal vaccines
  • Indications Influenza virus infections; Meningococcal infections; Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Novartis Institutes for BioMedical Research
  • Most Recent Events

    • 29 Nov 2011 New trial record
    • 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top